Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP

European Respiratory Journal

Volumn 37, Issue 3, 2011, Pages 595-603

  Boeck, L ^a   Eggimann, P ^a   Smyrnios, N ^c   Pargger, H ^a   Thakkar, N ^c   Siegemund, M ^a   Marsch, S ^b   Rakic, J ^a   Tamm, M ^a   Stolz, D ^a,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomarker; Midregional pro atrial natriuretic peptide; Procalcitonin; Prognosis; Risk stratification; Ventilator associated pneumonia

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; PROCALCITONIN;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEATH; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEMODYNAMICS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CALCITONIN; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; REGRESSION ANALYSIS; RISK; ROC CURVE; TREATMENT OUTCOME;

EID: 79953697671     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00023810     Document Type: Article

References (61)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903. (Pubitemid 34774654)
3. Melsen WG, Rovers MM, Bonten MJ. Ventilator-associated pneumonia and mortality: a systematic review of observational studies. Crit Care Med 2009; 37: 2709-2718.
4. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 2115-2121. (Pubitemid 36051151)
5. Kollef MH. The prevention of ventilator-associated pneumonia. N Engl J Med 1999; 340: 627-634. (Pubitemid 29093723)
6. Gursel G, Demirtas S. Value of APACHE II, SOFA and CPIS scores in predicting prognosis in patients with ventilator-associated pneumonia. Respiration 2006; 73: 503-508.
7. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, Creactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.
8. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176: 913-920. (Pubitemid 350097081)
9. Morgenthaler NG, Struck J, Thomas B, et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-236. (Pubitemid 38125732)
10. von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1973-1980. (Pubitemid 350046336)
11. Laukkanen JA, Kurl S, Ala-Kopsala M, et al. Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur Heart J 2006; 27: 1230-1237.
12. Brueckmann M, Huhle G, Lang S, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005; 112: 527-534. (Pubitemid 41060793)
13. Muller B, Suess E, Schuetz P, et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006; 260: 568-576. (Pubitemid 44772377)
14. Kruger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 2007; 33: 2069-2078. (Pubitemid 350164580)
15. Seligman R, Papassotiriou J, Morgenthaler NG, et al. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008; 34: 2084-2091.
16. Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86: 396-404. (Pubitemid 32109825)
17. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000; 19: 679-687.
18. Stolz D, Stulz A, Muller B, et al. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest 2007; 132: 504-514. (Pubitemid 47287555)
19. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52: 48-58.
20. Duflo F, Debon R, Monneret G, et al. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 2002; 96: 74-79. (Pubitemid 34032485)
21. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 48-53. (Pubitemid 40051694)
22. Seligman R, Meisner M, Lisboa TC, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006; 10: R125.
23. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-2602. (Pubitemid 44413058)
24. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34: 1364-1375.
25. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax 1999; 54: 867-873. (Pubitemid 29452793)
26. Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997; 45: 552-560. (Pubitemid 127806489)
27. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, Springer, 2001.
28. Park M, Hastie T. L1-regularization path algorithm for generalized linear models. J R Statist Soc B 2007; 69: 659-677.
29. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167. (Pubitemid 34764819)
30. Andersson B, Hall C. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function. J Card Fail 2000; 6: 208-213.
31. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301: 383-392.
32. Levitt JE, Vinayak AG, Gehlbach BK, et al. Diagnostic utility of Btype natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study. Crit Care 2008; 12: R3.
33. Meyer B, Huelsmann M, Wexberg P, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007; 35: 2268-2273. (Pubitemid 47476222)
34. Morgenthaler NG, Struck J, Christ-Crain M, et al. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005; 9: R37-R45.
35. Berdal JE, Stavem K, Omland T, et al. Prognostic merit of N-terminal-proBNP and N-terminal-proANP in mechanically ventilated critically ill patients. Acta Anaesthesiol Scand 2008; 52: 1265-1272.
36. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764-770. (Pubitemid 38296473)
37. Yap LB, Mukerjee D, Timms PM, et al. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126: 1330-1336. (Pubitemid 39391268)
38. Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133: 1088-1094. (Pubitemid 351685510)
39. Villar J, Blazquez MA, Lubillo S, et al. Pulmonary hypertension in acute respiratory failure. Crit Care Med 1989; 17: 523-526. (Pubitemid 19146083)
40. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610-620. (Pubitemid 41383938)
41. Mohapatra SS. Role of natriuretic peptide signaling in modulating asthma and inflammation. Can J Physiol Pharmacol 2007; 85: 754-759. (Pubitemid 350033273)
42. Vollmar AM. The role of atrial natriuretic peptide in the immune system. Peptides 2005; 26: 1086-1094. (Pubitemid 40725379)
43. Aiura K, Ueda M, Endo M, et al. Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat. Crit Care Med 1995; 23: 1898-1906.
44. Vaz Perez A, Doehner W, von Haehling S, et al. The relationship between tumor necrosis factor-a, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2010; 141: 39-43.
45. Lisboa T, Diaz E, Sa-Borges M, et al. The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest 2008; 134: 1208-1216.
46. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93. (Pubitemid 43955248)
47. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19. (Pubitemid 46122969)
48. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-1066.
49. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463-474.
50. Hillas G, Vassilakopoulos T, Plantza P, et al. CRP and PCT as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 2010; 35: 805-811.
51. Bertolini G, D'Amico R, Apolone G, et al. Predicting outcome in the intensive care unit using scoring systems: is new better? A comparison of SAPS and SAPS II in a cohort of 1,393 patients. GiViTi Investigators (Gruppo Italiano per la Valutazione degli interventi in Terapia Intensiva). Simplified Acute Physiology Score. Med Care 1998; 36: 1371-1382. (Pubitemid 128452867)
52. Leroy O, Meybeck A, d'Escrivan T, et al. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003; 29: 2170-2173.
53. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-1800.
54. Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754-1758. (Pubitemid 33010262)
55. Vincent JL, Opal SM, Marshall JC. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med, 38: 283-287.
56. Cohen NH. The real reasons not to rely on severity scores. Crit Care Med 2010; 38: 334-335.
57. Murray LS, Teasdale GM, Murray GD, et al. Does prediction of outcome alter patient management? Lancet 1993; 341: 1487-1491.
58. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-755.
59. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32: 2199-2206. (Pubitemid 39491798)
60. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197-1205. (Pubitemid 35222596)
61. Rello J, Rue M, Jubert P, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25: 1862-1867. (Pubitemid 27483968)